CA2666508A1 - Quinoline compounds - Google Patents
Quinoline compounds Download PDFInfo
- Publication number
- CA2666508A1 CA2666508A1 CA002666508A CA2666508A CA2666508A1 CA 2666508 A1 CA2666508 A1 CA 2666508A1 CA 002666508 A CA002666508 A CA 002666508A CA 2666508 A CA2666508 A CA 2666508A CA 2666508 A1 CA2666508 A1 CA 2666508A1
- Authority
- CA
- Canada
- Prior art keywords
- trifluoromethyl
- phenyl
- quinoline
- phenoxy
- methylsulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85258806P | 2006-10-18 | 2006-10-18 | |
US60/852,588 | 2006-10-18 | ||
PCT/US2007/081738 WO2008049047A2 (en) | 2006-10-18 | 2007-10-18 | Quinoline compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2666508A1 true CA2666508A1 (en) | 2008-04-24 |
Family
ID=38962854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002666508A Abandoned CA2666508A1 (en) | 2006-10-18 | 2007-10-18 | Quinoline compounds |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2074098A2 (zh) |
JP (1) | JP2010506954A (zh) |
CN (1) | CN101541751A (zh) |
AU (1) | AU2007311046A1 (zh) |
CA (1) | CA2666508A1 (zh) |
CL (1) | CL2007002996A1 (zh) |
MX (1) | MX2009003942A (zh) |
TW (1) | TW200825054A (zh) |
WO (1) | WO2008049047A2 (zh) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080186971A1 (en) * | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
GB0801416D0 (en) * | 2008-01-25 | 2008-03-05 | Piramed Ltd | Pharmaceutical compounds |
WO2009127822A2 (en) * | 2008-04-16 | 2009-10-22 | Biolipox Ab | Bis-aryl compounds for use as medicaments |
CA2742023A1 (en) * | 2008-11-19 | 2010-05-27 | Wyeth Llc | Polar quinazolines as liver x receptors ( lxrs ) modulators |
KR101699991B1 (ko) | 2009-02-11 | 2017-01-26 | 메르크 파텐트 게엠베하 | 신규의 아미노 아자헤테로시클릭 카르복사미드 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8198300B2 (en) | 2010-04-29 | 2012-06-12 | Universidad De Chile | Method for preventing tau protein aggregation and treating Alzheimer's disease with a quinoline derivative compound |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
MX2012014801A (es) * | 2010-07-08 | 2013-01-29 | Wyeth Llc | Esteres de quinolina nuevos utiles para el tratamento de transtornos cutaneos. |
ES2729754T3 (es) * | 2010-07-29 | 2019-11-06 | Merck Patent Gmbh | Carboxamidas azaheterocíclicas de aminas cíclicas |
AU2011332198A1 (en) * | 2010-11-24 | 2013-07-11 | Allergan, Inc. | Modulators of S1P receptors |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
KR20140088194A (ko) * | 2011-11-04 | 2014-07-09 | 에프. 호프만-라 로슈 아게 | 아릴-퀴놀린 유도체 |
SG11201405378VA (en) | 2012-03-02 | 2014-09-26 | Anayaderm Inc | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
EP2882496B1 (en) | 2012-08-13 | 2019-10-09 | The Rockefeller University | Treatment and diagnosis of melanoma |
EP3041834A4 (en) | 2013-09-04 | 2017-01-18 | Ralexar Therapeutics, Inc. | Liver x receptor (lxr) modulators |
EP3626712A3 (en) | 2013-09-04 | 2020-04-15 | Ellora Therapeutics, Inc. | Liver x receptor (lxr) modulators |
CN103539734B (zh) * | 2013-09-25 | 2015-10-14 | 上海交通大学 | 3-烯丙基喹啉的制备方法 |
WO2017027883A1 (en) * | 2015-08-13 | 2017-02-16 | San Diego State University Research Foundation | Atropisomerism for increased kinase inhibitor selectivity |
AU2017207291B2 (en) | 2016-01-11 | 2023-06-15 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
WO2018026877A1 (en) | 2016-08-05 | 2018-02-08 | Calitor Sciences, Llc | Process for preparing substituted quinolin-4-ol compounds |
CN111107902A (zh) * | 2017-03-14 | 2020-05-05 | 丹娜法伯癌症研究所 | Bax活化的用于诱导细胞死亡的小分子致敏 |
CA3078981A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
SG11202006853PA (en) * | 2018-01-29 | 2020-08-28 | Capulus Therapeutics Llc | Srebp inhibitors comprising a 6-membered central ring |
TWI748194B (zh) * | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Fxr有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
CA3127828A1 (en) * | 2019-01-28 | 2020-08-06 | Capulus Therapeutics, Llc | Srebp inhibitors comprising a thiophene central ring |
KR20220087497A (ko) | 2019-10-18 | 2022-06-24 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 병원성 혈관을 표적화하기 위한 화합물 및 방법 |
MX2022007164A (es) | 2019-12-13 | 2022-09-12 | Inspirna Inc | Sales metálicas y usos de estas. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5916891A (en) * | 1992-01-13 | 1999-06-29 | Smithkline Beecham Corporation | Pyrimidinyl imidazoles |
US5837719A (en) * | 1995-08-10 | 1998-11-17 | Merck & Co., Inc. | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
KR20070001922A (ko) * | 2003-12-12 | 2007-01-04 | 와이어쓰 | 심장혈관질환 치료에 유용한 퀴놀린 |
JP5097539B2 (ja) * | 2004-05-07 | 2012-12-12 | アムジエン・インコーポレーテツド | タンパク質キナーゼ調節剤および使用方法 |
CA2612765A1 (en) * | 2005-07-06 | 2007-01-18 | Merck And Co., Inc. | Antidiabetic oxazolidinediones and thiazolidinediones |
-
2007
- 2007-10-17 TW TW096138869A patent/TW200825054A/zh unknown
- 2007-10-18 MX MX2009003942A patent/MX2009003942A/es not_active Application Discontinuation
- 2007-10-18 AU AU2007311046A patent/AU2007311046A1/en not_active Abandoned
- 2007-10-18 CL CL200702996A patent/CL2007002996A1/es unknown
- 2007-10-18 JP JP2009533516A patent/JP2010506954A/ja not_active Withdrawn
- 2007-10-18 WO PCT/US2007/081738 patent/WO2008049047A2/en active Application Filing
- 2007-10-18 CA CA002666508A patent/CA2666508A1/en not_active Abandoned
- 2007-10-18 EP EP07844372A patent/EP2074098A2/en not_active Withdrawn
- 2007-10-18 CN CNA200780042885XA patent/CN101541751A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CN101541751A (zh) | 2009-09-23 |
EP2074098A2 (en) | 2009-07-01 |
WO2008049047A2 (en) | 2008-04-24 |
TW200825054A (en) | 2008-06-16 |
CL2007002996A1 (es) | 2008-06-13 |
AU2007311046A1 (en) | 2008-04-24 |
MX2009003942A (es) | 2009-04-24 |
WO2008049047A3 (en) | 2008-07-24 |
JP2010506954A (ja) | 2010-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2666508A1 (en) | Quinoline compounds | |
JP6734896B2 (ja) | ブロモドメイン阻害剤 | |
AU2008345681A1 (en) | Imidazo [1,2-a] pyridine compounds | |
US6509352B1 (en) | 2-oxoquinoline compounds and medicinal uses thereof | |
AU2008345696A1 (en) | Benzimidazole compounds | |
CA2710458A1 (en) | Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors | |
JP2006528193A (ja) | C−fmsキナーゼの阻害剤としてのキノリノン誘導体 | |
JPWO2006077821A1 (ja) | アルドステロン受容体調節剤としての芳香族スルホン化合物 | |
WO2012008564A1 (ja) | 含窒素芳香族複素環誘導体 | |
JP2006519846A (ja) | 複素環式キナーゼインヒビター:使用および合成の方法 | |
CA2742023A1 (en) | Polar quinazolines as liver x receptors ( lxrs ) modulators | |
CA2685002A1 (en) | Quinazoline compounds | |
EP2055703B1 (en) | Novel pyrimidine compound having benzyl(pyridylmethyl)amine structure and pharmaceutical comprising the compound | |
WO2013013614A1 (zh) | 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用 | |
AU2008345687A1 (en) | Pyrazolo [1,5-a] pyrimidine compounds | |
CA2630739A1 (en) | New compounds | |
AU2007333990A1 (en) | Benzimidazole TRPV1 inhibitors | |
CA2741537A1 (en) | Quinoxaline-based lxr modulators | |
JP2006515605A (ja) | アンドロゲンレセプターアンタゴニスト | |
EP1608643A1 (en) | 6-sulfonamide quinoline and chromene derivative as androgen receptor antagonists | |
JP6104807B2 (ja) | Ampk活性化剤として使用されるテトラヒドロキノリン誘導体 | |
JP2005513131A (ja) | チオクロメノン類 | |
MXPA06007287A (en) | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |
Effective date: 20131018 |